Founded in 2001, RayBiotech develops proteomics research tools for high-throughput protein detection, quantification and biomarker discovery. Its expertise centres on antibody arrays, protein arrays, multiplex immunoassays and proteomic analysis platforms that enable researchers to investigate complex biological pathways using limited sample volumes. The company introduced the first commercially available cytokine antibody array and has since expanded its capabilities across protein expression profiling, protein interaction studies and multiomics research. RayBiotech technologies support applications in cancer biology, immunology, inflammation, infectious disease, cardiovascular research, neuroscience, metabolism and drug discovery.
Its product portfolio includes Quantibody® multiplex ELISA arrays, RayPlex™ cytometric bead arrays, NexaTag® ultrasensitive immunoassays, protein and peptide arrays, ELISA kits, recombinant proteins and antibodies. These platforms support cytokine profiling, biomarker identification, signalling pathway analysis, post-translational modification research and flow cytometry workflows. In addition to research reagents, the company provides assay development, custom array design, proteomics services, antibody production and bioinformatics support.
Europa Biosite subsidiaries distribute RayBiotech products in Denmark, Estonia, Finland, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Sweden and Switzerland and the United Kingdom.
